Publication: The immunoreactivity profile of different HCV genotypes on immunoblot assay and its implications in the development of diagnostic assays
Issued Date
1997-09-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-0031459636
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.15, No.3 (1997), 133-140
Suggested Citation
Duangjit Kanistanon, Montana Neelamek, Tararaj Dharakul, Sirirurg Songsivilai The immunoreactivity profile of different HCV genotypes on immunoblot assay and its implications in the development of diagnostic assays. Asian Pacific Journal of Allergy and Immunology. Vol.15, No.3 (1997), 133-140. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/17963
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The immunoreactivity profile of different HCV genotypes on immunoblot assay and its implications in the development of diagnostic assays
Other Contributor(s)
Abstract
The immunoreactivity profiles of plasma samples obtained from patients infected with different hepatitis C virus (HCV) genotypes were studied using immunoblot assay containing multiple HCV antigens, the immunoblot assay was found to be positive in 81.5% of 195 blood donors who had anti-HCV antibodies as detected by second generation enzyme immunoassays. The samples reacted preferentially with the viral core, NS3-1 and NS5 antigens, and these reactivities were not influenced by HCV genotype. However, the reactivities with NS3-2 and NS4 antigens varied depending on HCV genotypes. The samples from patients infected with HCV genotype 1 reacted well with NS3-2 and NS4 antigens whereas those with other genotypes did not. In addition, samples with the unclassified HCV genotype reacted poorly with all antigens, except NS3-1. This study demonstrates the importance of the core, NS3-1 and NS5 antigens in the detection of antibodies against HCV, especially in areas where more than one genotypes of HCV are present. It also demonstrates that there is a need for further improvement of the currently used assays as new HCV genotypes are recently discovered.